Rimegepant for Endometriosis Pain in Women 18–45
Official title: A Phase II Clinical Trial to Test the Efficacy of Rimegepant for Endometriosis-Associated Pain
Funded at Mayo Clinic Arizona · NIH-11346506 · Data updated 2026-11-12
A Phase II study to see if the CGRP blocker rimegepant can reduce pelvic pain in women with endometriosis who are 18–45 years old.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mayo Clinic Arizona NIH-funded |
| Lab location | 1 site (Scottsdale, United States) |
| Project start | September 11, 2026 |
| Project end | August 31, 2029 |
| Funding year | 2026 |
| Award (this year) | $2,505,282 |
| NIH project number | 1R01HD121791-01 |
| Project ID | NIH-11346506 on NIH RePORTER |
Who could benefit from this research
✓Could help
Women aged 18–45 with histologically confirmed endometriosis and moderate-to-severe endometriosis-associated pain.
✕Less likely to help
Some participants may not experience pain reduction and could have side effects from the study medication.
What this research studies
This trial tests whether taking rimegepant every other day for 12 weeks can lessen non-menstrual pelvic pain and painful periods in women with confirmed endometriosis. It is a double-blind, placebo-controlled study enrolling about 132 participants to measure pain changes, reduce need for other pain medicines, and monitor safety. Researchers will also explore biomarker data from tissue CGRP to understand the treatment’s biology and potential predictors of response. If successful, the study could point to a non-hormonal option for managing endometriosis-related pain.
Why it matters
Potential benefit: If effective, participants may experience less pelvic pain and fewer headaches, improving daily comfort and reducing reliance on other analgesics.
How similar studies have gone: Previous CGRP-targeting approaches for pain have shown promise, but this is a targeted test in endometriosis and its results will inform future use.
Where this research is happening
-
Mayo Clinic Arizona
Scottsdale, United States Active
Researchers
- Principal investigator: Woldeamanuel, Yohannes Woubishet — Mayo Clinic Arizona
- Study coordinator: Woldeamanuel, Yohannes Woubishet
Related research
Other NIH-funded projects on the same topics.
-
Molecular clues to endometriosis-related infertility
This grant explores how molecular changes in endometriosis contribute to infertility, with the aim of finding better ways to diagnose and treat the condition.
-
Hormonal Influences on Inflammation in Endometriosis
A study in adult women with endometriosis looks at how hormones and immune pathways interact to influence inflammation and symptoms.
-
How genes influence endometriosis in women of different racial and ethnic backgrounds
The team will compare genetic changes in tissue from women of various races who have endometriosis to find molecular targets for better treatments.
-
Quantum diamond sensor endoscopy to map iron in endometriosis
A tiny quantum sensor built into an endoscope will map iron in endometriosis lesions to help diagnose the disease noninvasively.
-
Understanding how RPLP1 affects endometriosis and adenomyosis
A patient-focused look at how a ribosomal protein called RPLP1 may drive tissue changes in endometriosis and adenomyosis and what this could mean for future therapies.
-
CXCR4 methylation in endometriosis and its role as an early biomarker and non-hormonal therapy target
This project explores how changes in CXCR4 gene regulation may help diagnose endometriosis earlier and point toward non-hormonal treatments for the condition.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.